High Point Advisor Group LLC Syndax Pharmaceuticals Inc Transaction History

High Point Advisor Group LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$5.43 - $9.22 $57,612 - $97,824	-10,610 Closed	0 $0
Q4 2018 Feb 20, 2019	SELL	$3.6 - $8.42 $8,280 - $19,366	-2,300 Reduced 17.82%	10,610 $66,000
Q3 2018 Oct 24, 2018	BUY	$6.33 - $8.08 $81,720 - $104,312	12,910 New	12,910 $88,000
Q1 2018 Jun 11, 2018	SELL	$8.71 - $14.82 $96,768 - $164,650	-11,110 Closed	0 $0
Q4 2017 Feb 15, 2018	BUY	$7.8 - $12.94 $86,658 - $143,763	11,110	11,110 $102,000

240

101M

1.36M

618K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $631M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of High Point Advisor Group LLC, based on Form 13F filings with the SEC.

Stay updated on High Point Advisor Group LLC with notifications on news.